RMD

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Resmed Inc.

ResMed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Its comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, the company improves quality of life, reduces the impact of chronic disease, and lowers costs for consumers and healthcare systems in more than 140 countries.
CEO
Michael Farrell
Employees
7770
Headquarters

9001 Spectrum Center Blvd
San Diego, California 92123-1438
Phone: 18587462400
www.resmed.com

News

ResMed Inc Director Peter Farrell Sells 23,535 Shares
Feb 24, 2024 08:10am

ResMed Inc Director Peter Farrell Sells 23,535 Shares


Source:GuruFocus
Schneider Electric UK: University of Lincoln Modernises Edge Environments with Schneider Electric and RMD
Feb 20, 2024 14:30pm

Established 25 years ago, the University of Lincoln is highly dependent on SaaS applications for operational efficiency and to deliver a great student learning experience.Schneider Electric''s next…


Source:Finanz Nachrichten
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Feb 12, 2024 21:16pm

Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) - ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and stay on therapy. AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients. Addressing the


Source:ResMed
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea | RMD Stock News
Feb 12, 2024 21:16pm

ResMed (RMD) launches AirCurve 11 series devices, enhancing device therapy options for sleep apnea patients. The devices offer advanced features like Care Check-in, Personal Therapy Assistant, and compatibility with AirView and myAir app to support patients and provide insights to clinicians.


Source:Stock Titan
ResMed’s New AirCurve 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Feb 12, 2024 21:16pm

Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Q— —…—4 Resmed Inc Earnings Call Transcript
Feb 11, 2024 06:17am

Q2 2024 Resmed Inc Earnings Call Transcript


Source:GuruFocus
Here''s How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
Feb 01, 2024 20:00pm

ResMed (NYSE: RMD ) has outperformed the market over the past 15 years by 3.62% on an annualized basis producing an average annual return of 15.8%. Currently, ResMed has a market capitalization of $28.43 billion. Buying $100 In RMD: If an … Full story available on Benzinga.com


Source:Benzinga
Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed
Jan 29, 2024 20:24pm

Boris Schlossberg, BK Asset Management, joins ''Power Lunch'' to discuss SoFi, Warner Bros. Discovery and ResMed.


Source:CNBC
Decoding ResMed Inc (RMD): A Strategic SWOT Insight
Jan 26, 2024 05:12am

Decoding ResMed Inc (RMD): A Strategic SWOT Insight


Source:GuruFocus
ResMed CEO Mick Farrell goes one-on-one with Jim Cramer
Jan 26, 2024 01:12am

ResMed Chairman and CEO Mick Farrell joins ''Mad Money'' host Jim Cramer to talk quarterly results, weight loss drugs, growth in its medical device segment and more.


Source:CNBC